Travere Therapeutics Reports First Quarter 2021 Financial Results
May 06, 2021 16:01 ET
|
Travere Therapeutics, Inc.
Pivotal PROTECT Study of sparsentan in IgA nephropathy nears completion of patient enrollment; topline proteinuria data expected 3Q21 Net product sales of $47.4 million for the first quarter of...
Cytta Premiers Exciting new Website and Scintillating Cytta Show Double Feature
April 07, 2021 08:00 ET
|
Cytta Corp.
Las Vegas , April 07, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) is pleased to announce the Company’s newly designed and updated website at https://cytta.com/ is up and running and...
Cytta’s IGAN System Helps First Responders Achieve Daily Record Setting Vaccination Totals
March 22, 2021 10:00 ET
|
Cytta Corp.
Las Vegas , March 22, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA)To help deal with currently unprecedented Public Health crisis, Cytta provided our IGAN incident command technology to...
Texas Covid Vaccination Program Utilizing IGAN Screens on the YouTube Cytta Show
March 10, 2021 08:00 ET
|
Cytta Corp.
Las Vegas , March 10, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) We at Cytta are pleased and proud to be providing our IGAN incident command technology to assist in keeping Americans safe...
Initial Episode of the Cytta Show Screens on YouTube Today
March 03, 2021 08:00 ET
|
Cytta Corp.
Las Vegas , March 03, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) Cytta Corp. is pleased to announce that the inaugural version of the “Cytta Show” has now been posted on our YouTube...
Travere Therapeutics to Present at Upcoming Investor Conferences
February 22, 2021 16:30 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Company management will present at the following upcoming virtual investor conferences in...
Cytta CEO Announces Great Strides in SUPR and IGAN Product Development and Market Introductions
February 22, 2021 08:00 ET
|
Cytta Corp.
Las Vegas , Feb. 22, 2021 (GLOBE NEWSWIRE) -- --Cytta Corp (OTCPINK: CYCA) Cytta’s CEO, Gary Campbell is pleased to share the following open letter to all shareholders. The letter provides an...
Travere Therapeutics Announces Pricing of Public Offering of Common Stock
February 11, 2021 22:03 ET
|
Travere Therapeutics, Inc.
SAN DIEGO, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the pricing of an underwritten public offering of 6,550,000 shares of its common stock at a...
Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
October 09, 2020 16:01 ET
|
Retrophin, Inc.
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal...
Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
September 21, 2020 08:00 ET
|
Retrophin, Inc.
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety...